Moderna's Flu Shot Just Cleared Its Biggest Hurdle Yet

Where It Matters Most

The flu hits older adults hardest. Aging immune systems (a phenomenon scientists call immunosenescence) respond less vigorously to vaccines, which is exactly why high-dose and adjuvanted flu shots already exist for the 65-and-older crowd.

Moderna's data in this group looked encouraging. Among roughly 19,260 participants aged 65 and up, mFlusiva showed 27.4% relative efficacy over standard-dose comparators. That's basically the same benefit seen in the broader study population, which matters because older adults often see diminished vaccine performance.

The trial also tracked healthcare visits. Flu-related medical encounters dropped by 33.7% in the mFlusiva group compared to the standard vaccine group: 80 visits versus 120. Fewer doctor trips, fewer ER runs, fewer hospital beds occupied.

A Rocky Road to Get Here

This wasn't a straight shot to the finish line. Moderna's original application actually received a Refusal-to-File from the FDA, meaning the agency looked at the initial submission and essentially said, "This isn't ready for us to review." That's a painful rejection in pharma; it signals fundamental gaps in the data package.

Moderna regrouped. The company held a Type A meeting with the FDA's biologics division, agreed on a revised strategy, and resubmitted with age-stratified data. The new approach splits the approval into two pathways: traditional approval for adults 50–64, and accelerated approval for those 65 and older (with a required post-marketing study to confirm the benefit in that older group).

The advisory committee's unanimous vote suggests the revised strategy worked. Committee members reportedly described the trial as "well conducted" and the data as "robust in demonstrating additional efficacy."

The Billion-Dollar Seasonal Play

Approval would unlock something Moderna has been chasing since the pandemic windfall started fading: a recurring revenue stream that doesn't depend on COVID boosters.

The global seasonal flu vaccine market sits at roughly $8 to $9.5 billion per year, and it's growing. Analysts project it could reach $12 to $15 billion by the early 2030s, driven by aging populations, expanded recommendations, and premium-priced next-generation products.

Right now, improved vaccines (high-dose, adjuvanted, recombinant) account for only about 10% of global flu vaccine supply, produced by just four manufacturers. That's a wide-open lane for a new entrant with genuinely better data.

And Moderna isn't stopping at standalone flu shots. The company's combo vaccine, mCombriax (mRNA-1083), bundles flu and COVID protection into a single annual injection. Phase 3 data showed stronger immune responses against both flu strains and SARS-CoV-2 compared to existing vaccines given separately. If that also gets approved, the convenience factor alone could reshape how the world thinks about fall vaccination season.

The Competition Is Coming

Moderna may be first to the mRNA flu finish line, but it won't be alone for long. Pfizer and BioNTech have their own mRNA flu candidate in Phase 3 trials, with superiority data in adults 18–64. GSK has licensed an mRNA flu vaccine program from CureVac that has advanced into late-stage development.

Then there are the incumbents who won't go quietly. Sanofi (Fluzone High-Dose), GSK (Fluarix), and CSL Seqirus dominate the current market with decades of manufacturing scale, provider relationships, and brand trust. AstraZeneca even launched a version of FluMist you can administer at home.

Being first matters, though. Moderna would have a head start in building real-world evidence, securing formulary placement, and shaping prescriber habits before competitors arrive.

What Happens Next

The FDA's decision is due by August 5. If approved, Moderna expects mFlusiva to be available for the 2026–2027 flu season, meaning doses could start shipping within weeks of approval. Regulatory reviews are also underway in Europe, Canada, and Australia.

For Moderna, this is more than a product launch. It's an existential proof of concept. The company built its entire business model on the idea that mRNA is a platform, not a one-hit wonder. COVID made them famous. Flu could make them durable.

Nine scientists just said the data supports it. Now the FDA gets the final word.